6 Matching Annotations
  1. Aug 2022
  2. www.sciencedirect.com www.sciencedirect.com
    Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
    1
    1. jackiekrauss 29 Aug 2022

      Munro, A. P. S., Janani, L., Cornelius, V., Aley, P. K., Babbage, G., Baxter, D., Bula, M., Cathie, K., Chatterjee, K., Dodd, K., Enever, Y., Gokani, K., Goodman, A. L., Green, C. A., Harndahl, L., Haughney, J., Hicks, A., van der Klaauw, A. A., Kwok, J., … Appleby, K. (2021). Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): A blinded, multicentre, randomised, controlled, phase 2 trial. The Lancet, S0140673621027173. https://doi.org/10.1016/S0140-6736(21)02717-3 s

      is:article lang:en COVID-19 vaccine safety immunogenicity booster United Kingdom selection Oxford-AstraZeneca Pfizer-BioNTech reactogenicity cellular response vaccine availability
    Visit annotations in context

    Tags

    Annotators

    URL

    sciencedirect.com/science/article/pii/S0140673621027173
  3. www.medrxiv.org www.medrxiv.org
    https://medrxiv.org/cgi/content/10.1101/2022.03.08.22271822
    1
    1. jackiekrauss 29 Aug 2022

      Thuluva, S., Paradkar, V., Turaga, K., Gunneri, S., Yerroju, V., Mogulla, R., Kyasani, M., Manoharan, S. K., Medigeshi, G., Singh, J., Shaman, H., Singh, C., & Rao, A. V. (2022). Selection of optimum formulation of RBD-based protein sub-unit covid19 vaccine (Corbevax) based on safety and immunogenicity in an open-label, randomized Phase-1 and 2 clinical studies (p. 2022.03.08.22271822). medRxiv. https://doi.org/10.1101/2022.03.08.22271822

      is:preprint lang:en COVID-19 vaccine Corbevax vaccine safety immunogenicity optimum formulation RBD protein sub-unit vaccine adverse event cellular response safety concern
    Visit annotations in context

    Tags

    Annotators

    URL

    medrxiv.org/content/10.1101/2022.03.08.22271822v1
  4. Sep 2021
  5. www.science.org www.science.org
    Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2
    1
    1. jackiekrauss 03 Sep 2021

      Israelow, B., Mao, T., Klein, J., Song, E., Menasche, B., Omer, S. B., & Iwasaki, A. (2021). Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2. Science Immunology. https://doi.org/10.1126/sciimmunol.abl4509

      is:article lang:en COVID-19 vaccine adaptive immune determinants viral clearance primary infection variant of concern protection antibody response cellular immunity natural infection
    Visit annotations in context

    Tags

    Annotators

    URL

    science.org/doi/10.1126/sciimmunol.abl4509
  6. Jul 2021
  7. www.nejm.org www.nejm.org
    Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination | NEJM
    1
    1. Lu17Cheryl 29 Jul 2021

      Barouch, Dan H., Kathryn E. Stephenson, Jerald Sadoff, Jingyou Yu, Aiquan Chang, Makda Gebre, Katherine McMahan, et al. “Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination.” New England Journal of Medicine 0, no. 0 (July 14, 2021): null. https://doi.org/10.1056/NEJMc2108829.

      is:article lang:en COVID-19 Coronavirus pandemic immunity vaccine Johnson & Johnson-Janssen cellular immune response Ad26.COV2.S vaccine antibody Delta variant T-cell response acute respiratory syndrome SARS-CoV-2 SARS-CoV-2 variant
    Visit annotations in context

    Tags

    Annotators

    URL

    nejm.org/doi/full/10.1056/NEJMc2108829
  8. May 2021
  9. www.biorxiv.org www.biorxiv.org
    https://biorxiv.org/cgi/content/10.1101/2021.05.19.444825
    1
    1. jackiekrauss 22 May 2021

      Israelow, B., Mao, T., Klein, J., Song, E., Menasche, B., Omer, S. B., & Iwasaki, A. (2021). Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2. BioRxiv, 2021.05.19.444825. https://doi.org/10.1101/2021.05.19.444825

      is:preprint lang:en COVID-19 vaccine immunity viral clearance variant antibody response humoral immunity cellular adaptive immunity
    Visit annotations in context

    Tags

    Annotators

    URL

    biorxiv.org/content/10.1101/2021.05.19.444825v1
  10. Aug 2020
  11. medrxiv.org medrxiv.org
    https://doi.org/10.1101/2020.07.24.20161653
    1
    1. ErikStuchly 28 Aug 2020

      Ferretti, A. P., Kula, T., Wang, Y., Nguyen, D. M., Weinheimer, A., Dunlap, G. S., Xu, Q., Nabilsi, N., Perullo, C. R., Cristofaro, A. W., Whitton, H. J., Virbasius, A., Olivier, K. J., Baiamonte, L. B., Alistar, A. T., Whitman, E. D., Bertino, S. A., Chattopadhyay, S., & MacBeath, G. (2020). COVID-19 Patients Form Memory CD8+ T Cells that Recognize a Small Set of Shared Immunodominant Epitopes in SARS-CoV-2. MedRxiv, 2020.07.24.20161653. https://doi.org/10.1101/2020.07.24.20161653

      is:preprint lang:en COVID-19 T cell memory cell immunity development cellular response genome-wide screening epitope recognition spike protein homogeneity
    Visit annotations in context

    Tags

    Annotators

    URL

    medrxiv.org/cgi/content/short/2020.07.24.20161653